Harvard

Some lab experts say that Abbott's test is open to multiple variables, which could lead to improper use and incorrect test results.

The Harvard University spinout uses a combination of proprietary probes, nanoarrays, and convection PCR to target a broad set of molecular biomarkers.

In a preliminary study, the group reported high accuracy for the detection of breast cancer within an hour by combining a fluorescence flow cytometer with fine-needle biopsies.

The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals. 

The platform retained high sensitivity after exposure to plasma for more than one month, opening up a range of potential diagnostic applications, the researchers said.

Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.

Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.